Skip to content
Screener

Jazz Pharmaceuticals JAZZ Q2 2026 earnings

Reported August 3, 2026 · After market close

Revenue$1.2BBeat by $93.9M
EPS$5.71Miss by $0.47
Revenue estimate$1.1B
EPS estimate$6.18
“Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance. We remain focused on long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline through targeted corporate development and internal research and development. The combination of commercial execution, portfolio expansion and our strong financial foundation positions Jazz to deliver meaningful innovation for patients and substantial value for shareholders.”
Renee Gala

Next report

Nov 2, 2026 (Today)
Revenue estimate$1.2B
EPS estimate-$4.05

Financials

Q2 2026

Income statement

See full
Revenue$1.2B+15.5%
Operating income$248.2M+136%
Net income$192.8M+127%
EPS (diluted)$2.78+124%

Balance sheet

See full
Cash & equivalents$703.0M-40.9%
Total debt$4.4B-18.9%
Total equity$4.8B+29.6%
Total assets$11.1B+1.2%

Cash flow

See full
Operating cash flow$415.7M+368%
CapEx$18.1M+40.3%
Free cash flow$397.6M+424%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$13.49B+63.2%
Enterprise value$17.18B+39.1%
P/S2.9×+0.9×

Profitability

See full
FCF margin34.6%+3.6pp

Returns & leverage

See full
Debt / equity0.9×-0.5×
Current ratio1.8×+0.2×

Segments

By product

See full
Xywav$471.2M+13.5%
Epidiolex/Epidyolex$292.1M+16.1%
Zepzelca$105.8M+42.0%
Rylaze/Enrylaze$99.5M-1.2%
Defitelio/defibrotide$62.0M+28.9%

By geography

See full
Europe$97.4M+17.8%
All other$33.0M+23.6%

FAQ

When did Jazz Pharmaceuticals report Q2 2026 earnings?
Jazz Pharmaceuticals (JAZZ) reported Q2 2026 earnings on August 3, 2026 after market close.
What were Jazz Pharmaceuticals's Q2 2026 revenue and EPS?
Jazz Pharmaceuticals reported revenue of $1.2B and eps of $5.71 for Q2 2026.
Did Jazz Pharmaceuticals beat estimates in Q2 2026?
Revenue beat the consensus estimate of $1.1B by $93.9M. EPS missed the consensus estimate of $6.18 by $0.47.
How did Jazz Pharmaceuticals's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.5% from $1.0B a year earlier.
Where can I find Jazz Pharmaceuticals's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001232524-26-000044) and the 10-Q periodic report (0001232524-26-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.